Aminopyrimidine derivatives as LRRK2 modulators
AssigneeGenentech, Inc.
InventorsCharles Baker-Glenn, Daniel Jon Burdick, Mark Chambers, Bryan K. Chan, Huifen Chen, Anthony Estrada, Janet Gunzner-Tate, Daniel Shore, Zachary Kevin Sweeney, Shumei Wang, Guiling Zhao
Life of this patent
Estimating the term…
Abstract
Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n. X, R1, R2, R3, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
Claims15
A compound of formula IV:
- or a pharmaceutically acceptable salt thereof,
- wherein:
- m is 0 or 1;
- X is —NH— or —O—;
- R1 is:
- C1-6alkyl or C3-6cycloalkyl;
- R2 is:
- halo;
- or halo-C1-6alkyl;
- R3 is:
- halo;
- C1-6alkoxy;
- halo-C1-6alkoxy;
- C3-6cycloalkyloxy;
- or C3-6cycloalkyl-C1-6alkyloxy;
- R7 is:
- halo;
- C1-6alkyl;
- C1-6alkoxy;
- halo-C1-6alkyl;
- or halo-C1-6alkoxy;
- and
- R8 and R9 each independently is:
- hydrogen;
- C1-6alkyl;
- halo-C1-6alkyl;
- C1-6alkoxy;
- halo-C1-6alkoxy;
- hydroxy;
- hydroxy-C1-6alkyl;
- halo;
- nitrile;
- C1-6alkyl-carbonyl;
- C1-6alkyl-sulfonyl;
- C3-6cycloalkyl;
- C3-6cycloalkyl-C1-6alkyl;
- C3-6cycloalkyl-carbonyl;
- amino;
- or heterocyclyl;
- or R8 and R9 together with the atoms to which they are attached form a five- or six-membered ring.
The compound [4-(4-ethylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-2-fluoro-5-methoxy-phenyl]-morpholin-4-yl-methanone or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.